# Epirubicin in Treating Women Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer

> **NCT00253500** · PHASE2 · COMPLETED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 15 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** pegfilgrastim
- **DRUG:** epirubicin hydrochloride
- **PROCEDURE:** conventional surgery

## Key facts

- **NCT ID:** NCT00253500
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-06
- **Primary completion:** 2005-09
- **Final completion:** 2010-12
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2020-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00253500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00253500, "Epirubicin in Treating Women Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer". Retrieved via AI Analytics 2026-09-24 from https://api.ai-analytics.org/clinical/NCT00253500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*